Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates

Financial Performance - Cytek Biosciences reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and compared to a loss of $0.05 per share a year ago, indicating a significant earnings surprise of -125% [1] - The company posted revenues of $41.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 5.07%, and down from $44.86 million in the same quarter last year [2] - Over the last four quarters, Cytek has surpassed consensus EPS estimates two times and topped revenue estimates just once [2] Stock Performance - Cytek Biosciences shares have declined approximately 42.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $48.5 million, and for the current fiscal year, it is -$0.07 on revenues of $205.91 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Cytek's stock performance [5]